Membrane proteins constitute approximately one-third of all human proteins and represent nearly 60% of recognized drug targets, underscoring their critical roles in cellular signaling, transport mechanisms, and overall physiological maintenance. Understanding their interaction dynamics with various ligands is central to deciphering biological pathways and developing efficacious therapeutic agents. Among the techniques available, SPR stands out as a gold-standard, label-free technology enabling real-time monitoring of molecular binding kinetics. Despite this, the application of SPR to membrane proteins has been fraught with challenges, largely due to difficulties in immobilizing such proteins in a manner that preserves their native conformation and functional integrity.

Addressing this persistent impediment, the research team integrated the SpyCatcher-SpyTag system, a covalent conjugation technology known for its specificity and stability, with membrane scaffold protein (MSP)-based nanodisc technology. This fusion of approaches affords a robust and simplified strategy for tethering membrane proteins onto SPR sensor chips. The technique involves engineering an MSP fusion protein tagged with SpyTag, facilitating the construction of lipid-encapsulated nanodiscs that house the target membrane proteins in a near-native lipid milieu. These SpyTag-labeled nanodiscs can then be selectively captured by SpyCatcher molecules pre-immobilized onto CM5 sensor chips via conventional amine coupling chemistry, resulting in a highly specific and permanent attachment.

Central to the method’s success is the ability of the nanodiscs to preserve the membrane proteins’ structural integrity and functional activity by mimicking their physiological lipid environment. Conventional methods frequently rely on detergent solubilization or nonspecific adsorption, often leading to partial denaturation or loss of protein activity. In contrast, this SpyCatcher-SpyTag nanodisc system anchors the proteins covalently, ensuring stability throughout the SPR assay duration and enabling repeated experimental cycles without significant degradation or detachment.

In validating their platform, the team conducted comprehensive SPR analyses spanning three representative categories of membrane protein interactions. First, they examined protein–lipid interactions to understand how peripheral proteins associate with membrane components. Subsequently, transmembrane protein–antibody interactions were characterized, offering insights into antibody binding kinetics essential for therapeutic antibody development. Finally, they evaluated transmembrane protein–small molecule interactions, critical for drug candidate screening and optimization. Each assay demonstrated the method’s capacity to deliver high-fidelity kinetic measurements, paving the way for broader placement in membrane protein research workflows.

Notably, the binding interactions measured exhibited superior stability and reproducibility compared to traditional immobilization methods. The covalent linkage via SpyCatcher-SpyTag minimized artifacts such as protein aggregation or desorption under flow conditions. This enhanced robustness enables precise quantification of association and dissociation rates, affinities, and other parameters critical for understanding molecular mechanisms. The method’s versatility also allows for adaptation to a wide range of membrane proteins and ligand types, thus broadening the scope of SPR applications.

The profound implications of this technology extend beyond basic science. Given that membrane proteins serve as targets for most clinically significant drugs, improved tools for their study accelerate rational drug design processes. This immobilization approach facilitates detailed mechanistic studies, aids in screening potential therapeutic compounds, and enhances antibody characterization, potentially reducing time and cost associated with later-stage drug development. Researchers anticipate that this technique will become a mainstay in pharmacological and biophysical laboratories worldwide.

The integration of SpyCatcher-SpyTag conjugation with MSP-nanodisc technology also exemplifies a shift towards leveraging bioorthogonal chemistries and biomimetic systems in analytical assays. Where earlier techniques often compromised biomolecule functionality, these contemporary strategies embrace molecular precision and biological relevance. This method stands as a model for future innovations seeking to bridge the gap between in vitro analytical tools and in vivo biological complexity.

While the study focused on three interaction types, the fundamental principles underlying this immobilization method suggest it could be extended to other challenging membrane protein systems, including ion channels, G-protein-coupled receptors (GPCRs), and transporters. The capacity to maintain proteins within a tailored lipid environment and affix them stably to sensor surfaces may lead to breakthroughs in characterizing these complex entities, which have traditionally been intractable using conventional SPR protocols.

Furthermore, the strategy’s modular nature allows for customization of the nanodisc composition, enabling researchers to mimic specific cellular membrane environments, potentially unlocking new insights into the influence of lipid context on protein function. Such customization adds an additional layer of biological relevance which has been difficult to achieve with previous immobilization methodologies.

Overall, this novel SPR immobilization approach represents a harmonious convergence of molecular biology, bioengineering, and analytical chemistry, collectively overcoming a formidable technical bottleneck in membrane protein research. As membrane proteins continue to be at the frontier of medical and biological inquiry, the emergence of reliable, efficient analysis platforms will drive deeper understanding and innovative therapeutics.

This work spearheaded by WANG Junfeng’s team is poised to achieve widespread adoption in academic and industrial settings, heralding a transformative shift in the landscape of membrane protein assays. With its publication slated in Analytical Chemistry, this pioneering research will undoubtedly inspire subsequent developments and foster collaboration across biotechnology, pharmaceutical, and research communities worldwide.

Subject of Research: Membrane protein immobilization for surface plasmon resonance assays using SpyCatcher–SpyTag conjugation and MSP-nanodisc technology

Article Title: A Robust Immobilization Method for Membrane Protein SPR Assays Using SpyCatcher–SpyTag

News Publication Date: 31-Aug-2025

Web References: https://doi.org/10.1021/acs.analchem.5c01671

Keywords

Physical sciences

GPCRs stand as paramount signaling conduits in eukaryotic cells, orchestrating myriad physiological responses by coupling to heterotrimeric G proteins. These G proteins, which vary widely in subtype, interact with GPCRs predominantly via their highly divergent C-terminal regions of the α-subunit. Traditionally, the recruitment and activation of different G proteins by a single GPCR was considered a somewhat uniform process. However, subtle determinants that govern selective engagement of specific G protein subtypes have remained elusive.

The recent investigation pivots around SBI-553, an allosteric molecule previously shown to inhibit Gq/11 protein activation mediated by the neurotensin receptor 1 (NTSR1). The essential question addressed was whether this antagonism stemmed solely from indirect mechanisms such as β-arrestin recruitment or if direct obstruction of G protein binding sites occurred. By engineering chimeric G protein constructs that swapped the critical C-terminal residues between Gq and GoA proteins, the study decisively demonstrated that the primary structure of the G protein C terminus dictates the effectiveness of SBI-553-mediated antagonism.

Specifically, when the C-terminal five amino acids of GoA were replaced with those of Gq, the resulting chimera became susceptible to inhibition by SBI-553, despite native GoA being fully permissive to G protein activation in SBI-553’s presence. Conversely, introducing GoA’s C-terminal residues into Gq attenuated the antagonist’s potency, underpinning the indispensable role of these residues in determining receptor-G protein specificity. By extending this approach further and exchanging the terminal 13 residues in Gq with those from GoA, the construct exhibited near-complete insensitivity to SBI-553 across all but the highest tested concentrations, emphasizing cumulative effects rather than single residues driving this specificity.

Intriguingly, point mutations targeting four unique residues within the Gq C terminus, hypothesized to mediate SBI-553 sensitivity, fell short of recapitulating the full C-terminal swap’s effects. Each single substitution—be it V359Y, N357G, Y356C, or L351N—allowed neurotensin-induced activation to proceed unaffected, with SBI-553 maintaining its full antagonistic capacity. This finding underscores that the allosteric modulation and selectivity are not directed by individual residues but by the holistic conformational dynamics enabled by the entire C-terminal segment.

Delving deeper into the structural underpinnings, the researchers leveraged high-resolution cryo-electron microscopy structures of NTSR1 bound to neurotensin and the respective mini-G proteins. Absent SBI-553, both GoA and Gq maintain a ‘closed’ α-helical conformation within the receptor intracellular core, overlapping extensively in space. However, when modeling the binding of SBI-553 onto these complexes, steric clashes emerge, implying that coexistence demands conformational rearrangements.

Notably, in the presence of SBI-553, GoA undergoes a striking transformation to an ‘open’ conformation. Here, the Gα C-terminal helix tilts approximately 14 degrees towards transmembrane helix 1 and unwinds partially over the last five residues. This repositioning retracts the α-helix about 4 angstroms shallower into the receptor and creates van der Waals contacts with SBI-553’s molecular moieties. The uniqueness of this conformation stands out, as comprehensive superpositions of known GPCR-G protein complexes fail to reveal such alternative binding modes, suggesting SBI-553 itself induces this rare structural state.

This alternative binding paradigm can explicate why SBI-553 selectively inhibits Gq/11 proteins: the energetic feasibility of adapting this shallow-binding ‘open’ conformation varies among G protein subtypes. Using in silico homology modeling, the team examined multiple G proteins, including Gq, G11, GoB, Gi variants, and G12/13, by substituting their C-terminal residues onto the GoA ‘open’ conformation template. The models revealed that certain residues in Gq/11 impose energetic penalties—such as needing to adopt disfavored backbone dihedral angles—that impede adopting the open conformation compatible with SBI-553 binding. Conversely, G12 and G13, despite slight energetic concessions, gain stabilizing van der Waals interactions with SBI-553, potentially explaining their differential sensitivities.

Beyond the direct structural compatibility, the functional consequences of SBI-553 extend to receptor activation dynamics. The compound interacts with the crucial E/DRY motif of NTSR1, specifically targeting the arginine residue, thereby disrupting the receptor’s inactive conformation and facilitating an active-like state. Concurrently, the induced ‘open’ G protein conformation resembles intermediate states along the G protein activation pathway, indicating that SBI-553 modulates receptor and transducer activation states in a coordinated manner rather than purely blocking their association.

Attempts to solve the empirical structure of an NTSR1–Gq–SBI-553 complex have thus far been unsuccessful, likely due to the biochemical incompatibility stemming from Gq’s reluctance or inability to adopt the necessary open conformation occluded by SBI-553. This aligns with the observed pharmacological profile where SBI-553 antagonizes Gq but not GoA in cellular assays.

These findings herald a conceptual leap in understanding how allosteric modulators can reprogram GPCR signaling specificity. Instead of acting merely as inhibitors or activators, such compounds can sculpt the conformational landscape of receptor-transducer interfaces, selectively stabilizing or destabilizing specific protein-protein interactions based on subtle structural features. This nuanced mechanism affords unprecedented finesse in therapeutic targeting by enabling pathway-selective modulation, potentially minimizing adverse off-target effects attributed to promiscuous G protein activation.

Moreover, the study synergizes structural biology, protein engineering, and computational modeling to elucidate the molecular grammar governing receptor-G protein coupling specificity. The profound implications extend to numerous GPCR systems, given the conserved architecture yet diverse functional outcomes mediated via distinct G protein subtypes. By exploiting the inherent conformational plasticity of Gα subunits and the receptor intracellular crevice, bespoke allosteric ligands like SBI-553 can be rationally designed to tailor signaling cascades.

In the broader context of pharmacology, this work underscores the value of examining receptor-transducer interactions beyond traditional agonism and antagonism frameworks. Allosteric modulators that influence protein conformational ensembles may emerge as a predominant class of modulators that achieve selective signaling bias in complex physiological environments. This approach holds promise for conditions where specific G protein pathways contribute to pathological states, such as neurological disorders, cardiovascular diseases, and cancer.

In conclusion, the pioneering elucidation of SBI-553’s mode of action illustrates how fine structural determinants within the G protein C terminus govern the allosteric modulation landscape at GPCRs. The insights gleaned define new avenues for precision drug design, empowering the development of selective signaling modulators that harness the nuanced conformational dynamics between receptors and their diverse transducer partners.

Subject of Research:

The study focuses on the molecular determinants of G protein subtype selectivity in GPCR signaling, specifically examining how an allosteric modulator (SBI-553) influences the coupling preferences of the neurotensin receptor 1 (NTSR1) towards Gq/11 versus GoA proteins by altering G protein C-terminal conformation.

Article Title:

Designing allosteric modulators to change GPCR G protein subtype selectivity

Article References:

Moore, M.N., Person, K.L., Robleto, V.L. et al. Designing allosteric modulators to change GPCR G protein subtype selectivity. Nature (2025). https://doi.org/10.1038/s41586-025-09643-2

Image Credits:

AI Generated

Understanding mRNA maturation is vital, as it serves as the precursor to protein synthesis. This complex process involves several steps, starting from transcription by RNA polymerase II and culminating in the production of a mature mRNA molecule ready for translation. The study reveals that two key post-translational modifications—O-GlcNAcylation and phosphorylation—act on specific proteins associated with RNA polymerase II, influencing their binding affinity and functionality.

The authors propose that O-GlcNAcylation, the addition of N-acetylglucosamine to serine or threonine residues of proteins, serves as a marker for cellular nutritional status. This modification can modulate protein interactions and stability, creating a flexible regulatory mechanism. The study provides a detailed analysis of how alterations in O-GlcNAc levels can affect the recruitment of regulatory proteins to RNA polymerase II, thereby impacting mRNA processing.

Phosphorylation, on the other hand, is a well-established mechanism that modifies protein activity and behavior through the addition of phosphate groups. In the context of RNA polymerase II, the phosphorylation of serine residues in the C-terminal domain (CTD) can influence the transition from transcription initiation to elongation. Gondane and Itkonen’s research highlights how the competitive nature of O-GlcNAcylation and phosphorylation creates a nuanced regulatory environment that can change quickly in response to cellular signals.

Moreover, the study investigates how these modifications can attract or expel certain proteins from the RNA polymerase II complex, thus effectively controlling the mRNA maturation process. The dynamic nature of these interactions suggests a sophisticated regulatory network whereby cellular signals can lead to rapid changes in gene expression and protein production, providing cells with the ability to adapt to varying environmental conditions.

A particularly striking aspect of this research is the experimental approach utilized by the authors. Employing cutting-edge techniques such as mass spectrometry and live-cell imaging, the study effectively elucidates the dynamic changes in protein interactions that occur during mRNA maturation. This not only bolsters the credibility of their findings but also sets a precedent for future investigations exploring other aspects of gene regulation.

Furthermore, the implications of this research extend beyond basic biology; it offers potential therapeutic insights for diseases where mRNA maturation is disrupted, including various cancers and neurodegenerative disorders. Understanding how O-GlcNAcylation and phosphorylation interact could pave the way for novel intervention strategies aimed at restoring proper gene regulation in diseased states.

As we navigate through the mechanisms of cellular regulation elucidated in this comprehensive study, it becomes apparent that the interplay between O-GlcNAcylation and phosphorylation is crucial not just for basic cellular function but for the intricate balance of life itself. The ability of cells to fine-tune gene expression through such modifications underscores the complexity of cellular signaling pathways, and highlights a new frontier in our understanding of molecular biology.

In conclusion, the findings presented by Gondane and Itkonen mark a significant advancement in our comprehension of RNA polymerase II function and mRNA maturation. The study opens numerous avenues for further research, particularly in exploring how these regulatory mechanisms can be manipulated for therapeutic benefits. As the field moves forward, the significance of post-translational modifications like O-GlcNAcylation and phosphorylation cannot be overstated; they represent key players in the grand orchestration of cellular physiology.

The future of research in this domain holds great promise, as scientists continue to unravel the complexities of protein interactions and their implications in health and disease. The insights gained from this study not only contribute to the foundational knowledge of molecular biology but also inspire future endeavors aimed at leveraging this understanding in the development of innovative treatments and therapeutic approaches.

The work of Gondane and Itkonen thus serves as a cornerstone for aspiring researchers in the field, encouraging a deeper exploration of the dynamic regulatory mechanisms that govern gene expression and cell function. With such promising avenues of exploration on the horizon, the journey to discover the full potential of O-GlcNAcylation and phosphorylation in cellular biology is sure to yield exciting results in the years to come.

Subject of Research: The Dynamic Role of O-GlcNAcylation and Phosphorylation in mRNA Maturation

Article Title: Dynamic O-GlcNAcylation and phosphorylation attract and expel proteins from RNA polymerase II to regulate mRNA maturation.

Article References:

Gondane, A., Itkonen, H.M. Dynamic O-GlcNAcylation and phosphorylation attract and expel proteins from RNA polymerase II to regulate mRNA maturation.
J Biomed Sci 32, 39 (2025). https://doi.org/10.1186/s12929-025-01135-9

Image Credits: AI Generated

DOI:

Keywords: O-GlcNAcylation, phosphorylation, RNA polymerase II, mRNA maturation, gene expression.